Experimental Investigation of the Oncobiological Effects of Apitoxin in a Sarcoma-45 Model

Abstract

Intensive research is currently being conducted worldwide into novel biologically active compounds and integrative therapeutic approaches for the treatment of malignant diseases. Bee venom (apitoxin) is a natural substance with a complex biological composition containing peptides, enzymes, and other bioactive components. Over recent decades, preclinical studies have increasingly focused on the oncobiological activity of melittin, phospholipase A2, and other peptide components of bee venom.

The aim of the present study was to describe the antitumour effects of bee venom observed in an experimental Sarcoma-45 tumour model and to provide a brief overview of the relevant preclinical literature. Native dried apitoxin obtained by electrical stimulation was administered to rats implanted with Sarcoma-45 tumours using different solvent systems. The control group received no treatment.

Marked tumour regression was observed in the apitoxin-treated groups by days 3–4 of treatment. By day 10, tumour size had decreased to approximately half of the initial volume. The treated animals demonstrated improvement in general condition, increased activity, and improved appetite, whereas the control group exhibited progressive tumour growth and significant mortality.

These findings suggest that the bioactive components of bee venom may influence several biological mechanisms involved in tumour progression and may also affect immunological and inflammatory regulatory pathways. Although further controlled preclinical and clinical studies are required to assess clinical applicability in humans, the available molecular, cellular, and experimental evidence supports further investigation of apitoxin within the field of integrative oncology.